Antibody Information
General Information of This Antibody
| Antibody ID | ANI0PEKTF |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | ZHER2-ABD |
|||||
| Antibody Type | Fusion protein (FP) |
|||||
| Antigen Name | Receptor tyrosine-protein kinase erbB-2 (ERBB2) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
ZHER2-ABD-mcMMAF [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.01 nM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
HER2-expressing cell lines were incubated with concentration series of the drug conjugates, and the viability of the cells was measured.
|
||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.20 nM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
HER2-expressing cell lines were incubated with concentration series of the drug conjugates, and the viability of the cells was measured.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.20 nM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
HER2-expressing cell lines were incubated with concentration series of the drug conjugates, and the viability of the cells was measured.
|
||||
| In Vitro Model | Breast adenocarcinoma | AU565 cells | CVCL_1074 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
12.00 nM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
HER2-expressing cell lines were incubated with concentration series of the drug conjugates, and the viability of the cells was measured.
|
||||
| In Vitro Model | Ovarian serous cystadenocarcinoma | SK-OV-3 cells | CVCL_0532 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
215 nM
|
Moderate HER2 expression (HER2 ++) | ||
| Method Description |
HER2-expressing cell lines were incubated with concentration series of the drug conjugates, and the viability of the cells was measured.
|
||||
| In Vitro Model | Lung adenocarcinoma | A-549 cells | CVCL_0023 | ||
ZHER2-ABD-mcMMAE [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
8.20 nM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
HER2-expressing cell lines were incubated with concentration series of the drug conjugates, and the viability of the cells was measured.
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
24.00 nM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
HER2-expressing cell lines were incubated with concentration series of the drug conjugates, and the viability of the cells was measured.
|
||||
| In Vitro Model | Breast adenocarcinoma | AU565 cells | CVCL_1074 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.